Filing Details

Accession Number:
0001415889-23-003007
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-22 17:00:38
Reporting Period:
2023-02-21
Accepted Time:
2023-02-22 17:00:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1551152 Abbvie Inc. ABBV Pharmaceutical Preparations (2834) 320375147
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1951400 C Perry Siatis 1 N. Waukegan Road
North Chicago IL 60064
Evp, Gc And Secretary No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.01 Par Value Acquisiton 2023-02-21 7,364 $93.50 39,532 No 4 M Direct
Common Stock, $0.01 Par Value Disposition 2023-02-21 3,431 $150.73 36,101 No 4 S Direct
Common Stock, $0.01 Par Value Disposition 2023-02-21 3,933 $151.29 32,168 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (Right to buy) Disposition 2023-02-21 7,364 $93.50 7,364 $93.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-02-16 2033-02-15 No 4 M Direct
Footnotes
  1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.49, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.